surmount-1 tirzepatide trial obesity without diabetes for Obesity: Highlights from the Comparison of Clinical Efficacy and
Description
Biology of incretins: GLP-1 and GIP
The trade-off is real, and the regulatory floor sits lower
The secondary outcomes included comparing the proportion and duration of time spent in the target range at 24 and 52 weeks
Numerous studies have highlighted the efficacy of naltrexone in promoting weight loss and reducing food cravings
01200-X/asset/187876e5-369e-466d-8bb1-a92ee0475cd1/main.assets/gr3.jpg)
Heise T, Mari A, DeVries JH, et al
The most common adverse events associated with tirzepatide were nausea, constipation, and nasopharyngitis, with a low frequency of gastrointestinal events
00656-2/asset/38c98550-9ec2-44e8-ba6a-dbb815075666/main.assets/gr1_lrg.jpg)
